Loading stock…

Huadong Medicine Co., Ltd (000963) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Huadong Medicine Co., Ltd

000963Market cap $7.06BPrice $4.0

Country🇨🇳China

SectorHealthcare

IndustryHealthcare Services

Develops and sells pharmaceuticals, medical devices, and health products across China, spanning diabetes, oncology, and cosmetic dermatology lines. It also runs a booming aesthetic medicine business, making it one of China's few drugmakers profiting from the beauty boom.

In Bastion Portfolios?

52W Return-28%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+4%5

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+5%4

Rev CAGR (5y)+4%3

Earnings Forecast

EPS Growth Y+1+14%7

EPS Growth Y+2+14%7

EPS Growth Y+3+23%8

Quality

Margins

EBIT Margin9%4

Net Income Margin8%5

Free Cash Flow Margin6%5

Debt

Net Debt/EBITDA-0.710

Efficiency

ROE14%6

ROA9%8

Earnings Stability77

GEAR+STRONG79

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)156

P/E Ratio (Forward 3y)98

P/BV1.97

EV Multiples

EV/EBITDA Fwd88

EV/EBIT Fwd109

Yield

Free Cash Flow Yield5.9%7

Dividend Yieldna–

Momentum

Short term

1 month return+1%8

3 month return-5%5

YTD return-29%2

Mid term

Price vs 52wHigh64%3

1 year return-33%2

Long term

3 year return-31%1

5 year return-9%3

Risk Shield

Price Risk

Beta0.210

Volatility31%7

Free Cash Flow

Free Cash Flow Margin6%5

Free Cash Flow Yield5.9%7

Quality

ROCE16%8

Earnings Stability77

Net Debt/EBITDA-0.710

02Growth

Is it actually growing, and how fast?

000963Huadong Medicine Co.

Revenue FY25$6.2B

GROWTH RATING↗

AVERAGE36 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+4%5

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+14%7

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 5%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 36% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 4%/yr over the last 3 years and is set to keep growing around 5%/yr.

WEAKNESSES

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

000963Huadong Medicine Co.

Total return Current61.9%

Price return Current40.1%

MOMENTUM RATING↗

WEAK20 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-5%5

YTD return-29%2

MID & LONG-TERM▾SCORE

% of 52-week high64%3

1-year return-33%2

3-year return-31%1

5-year return-9%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+1%).

WATCH

Returns sit at the market level over three months (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-31% over three years and -8.6% over five), behind 80% of the market.

It's down 33% over the past year, now 36% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-29%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Huadong Medicine Co., Ltd. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

000963Huadong Medicine Co.

Revenue FY25$6.2B

GROWTH RATING↗

AVERAGE36 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+4%5

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+14%7

EPS growth, FY27E+14%7

EPS growth, FY28E+23%8

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 14%/yr vs revenue 5%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 36% of companies worldwide.

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 4%/yr over the last 3 years and is set to keep growing around 5%/yr.

WEAKNESSES

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

000963Huadong Medicine Co.

Total return Current61.9%

Price return Current40.1%

MOMENTUM RATING↗

WEAK20 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return-5%5

YTD return-29%2

MID & LONG-TERM▾SCORE

% of 52-week high64%3

1-year return-33%2

3-year return-31%1

5-year return-9%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+1%).

WATCH

Returns sit at the market level over three months (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-31% over three years and -8.6% over five), behind 80% of the market.

It's down 33% over the past year, now 36% below its 52-week high. That is lagging the market.

The stock is underperforming so far this year (-29%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Huadong Medicine Co., Ltd. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community